Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare Conference
June 05 2014 - 8:30AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that
Greg Madison, the Company's Chief Operating Officer, will present a
corporate overview at the 35th Annual Goldman Sachs Global
Healthcare Conference to be held from June 10-12, 2014 at the
Terranea Resort in Rancho Palos Verdes, CA.
Mr. Madison's presentation will take place on Thursday, June 12,
at 10:00 a.m. Pacific Time (1:00 p.m. ET).
A live audio webcast of Mr. Madison's presentation will be
accessible within the Investor Relations section of the Company's
website at http://investors.keryx.com. An archived version of this
webcast will be available following the conclusion of the live
presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused
on bringing innovative therapies to market for patients suffering
from renal disease. In the United States, ZerenexTM (ferric
citrate) is currently under review by the Food and Drug
Administration (FDA) for the treatment of hyperphosphatemia in
dialysis-dependent chronic kidney disease (CKD) patients. In
January 2014, ferric citrate was approved for the treatment of
patients with all stages of CKD in Japan, where it is being
marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc.
and Torii Pharmaceutical Co. Ltd.
CONTACT: Amy Sullivan
Vice President - Corporate Development and Public Affairs
Keryx Biopharmaceuticals, Inc.
Tel: 617.466.3447
E-mail: amy.sullivan@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2024 to May 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From May 2023 to May 2024